SOPH

SOPHiA Genetics SA

7.63

Oct 30 • 3:59 PM ET -0.34 (-4.27%)

7.63

Aftermarket • 5:15 PM ET 0.00 (0.00%)

Healthcare Health Information Services Switzerland Small NASD

Peers: TEM ILMN QGEN CAI PSNL FLGT WGS VCYT MYGN GH

| Held by: ONEQ GWX MEDI AIMS GNMX

Scroll to Statements

Index	-
Market Cap	649.53M
Enterprise Value	603.69M
Income	-80.88M
Sales	86.17M
Book/sh	0.98
Cash/sh	1.26
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	415
IPO	Jul 23, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	7.54
P/B	7.81
P/C	6.03
P/FCF	-
EV/EBITDA	-
EV/Sales	7.01
Quick Ratio	2.55
Current Ratio	2.69
Debt/Eq	0.74
LT Debt/Eq	0.71
Option/Short	Yes / Yes

EPS (ttm)	-1.15
EPS next Y	-0.63
EPS next Q	-0.20
EPS this Y	19.83%
EPS next Y	33.26%
EPS next 5Y	32.33%
EPS past 3/5Y	5.00% -13.68%
Sales past 3/5Y	17.56% 22.16%
EPS Y/Y TTM	-4.80%
Sales Y/Y TTM	23.65%
EPS Q/Q	9.04%
Sales Q/Q	27.22%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	-42.86% 7.32%

Insider Own	27.42%
Insider Trans	-2.57%
Inst Own	43.71%
Inst Trans	21.59%
ROA	-43.02%
ROE	-101.22%
ROIC	-56.87%
Gross Margin	66.63%
Oper. Margin	-84.33%
Profit Margin	-93.86%
SMA20	4.14%
SMA50	-3.09%
SMA200	28.24%
Trades

Shs Outstand	85.13M
Shs Float	61.78M
Short Float	1.62%
Short Ratio	1.68
Short Interest	1.00M
52W High	8.98 -15.03%
52W Low	3.83 99.22%
Volatility	4.82% 6.84%
ATR (14)	0.46
RSI (14)	51.58
Beta	1.08
Rel Volume	0.64
Avg Volume	595.22K
Volume	379,150

Perf Week	3.81%
Perf Month	-4.98%
Perf Quarter	34.09%
Perf Half Y	43.42%
Perf YTD	63.38%
Perf Year	47.01%
Perf 3Y	98.18%
Perf 5Y	-46.23%
Perf 10Y	-
Recom	1.00
Target Price	9.75
Prev Close	7.97
Price	7.63
Change %	-4.27%

Consensus

Strong Buy

Avg. Price Target

$9.75

Implied Upside

+27.8%

Analysts9incl. previous ratings

Rating Distribution7 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 20, 2026	Initiated	HH.C. Wainwright	Buy	$12	+57.3%
Dec 18, 2024	Initiated	CCraig Hallum	Buy	$11	+44.2%
Aug 07, 2024	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$10 → $5	-34.5%
Jun 27, 2024	Initiated	GGuggenheim	Buy	$6	-21.4%
Nov 29, 2023	Initiated	RRBC Capital Mkts	Outperform	$8	+4.8%
Jul 05, 2023	Resumed	JJP Morgan	Overweight	$10	+31.1%
Jan 03, 2023	Initiated	BBTIG Research	Buy	$6	-21.4%
Nov 23, 2022	Initiated	CCredit Suisse	Neutral	$2	-73.8%
Oct 15, 2021	Resumed	CCowen	Outperform
Aug 17, 2021	Initiated	MMorgan Stanley	Overweight	$24	+214.5%
Aug 17, 2021	Initiated	JJP Morgan	Overweight	$23	+201.4%
Aug 17, 2021	Initiated	CCredit Suisse	Outperform	$22	+188.3%
Aug 17, 2021	Initiated	CCowen	Outperform

Oct-26-26 06:07PM	SOPHiA Genetics Must Prove Its US Surge Can Survive A Gross Margin Squeeze (Earnings Whispers)
Oct-20-26 08:00AM	SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026 (PR Newswire) +6.78%
Oct-08-26 09:00AM	SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology (PR Newswire)
Aug-05-26 05:45AM	SOPHiA GENETICS partners with AstraZeneca for oncology diagnostics (Hospital Management) -7.89%
Aug-04-26 03:00PM	Sophia Genetics SA (SOPH) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.21%
11:23AM	Loading…
11:23AM	SOPH Stock Heads For Best Day In Over 8 Months Whats Driving Todays Super Rally? (Stocktwits)
06:45AM	SOPHiA GENETICS Reports Second Quarter 2026 Results (PR Newswire)
06:15AM	SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies (PR Newswire)
Jul-21-26 08:00AM	SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026 (PR Newswire)
Jun-22-26 08:25AM	SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting (PR Newswire)
Jun-19-26 08:00AM	SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jun-16-26 09:21PM	SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares (PR Newswire) +6.29%
04:20PM	SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares (PR Newswire)
Jun-10-26 08:00AM	SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting (PR Newswire)
Jun-04-26 08:00AM	SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center (PR Newswire)
05:00AM	Loading…
May-13-26 05:00AM	Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. (PR Newswire)
May-05-26 06:45AM	SOPHiA GENETICS Reports First Quarter 2026 Results (PR Newswire)
Apr-21-26 08:00AM	SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026 (PR Newswire)
Apr-16-26 08:00AM	Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026 (PR Newswire)
Mar-04-26 08:02PM	Sophia Genetics SA (SOPH) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Mar-03-26 01:30PM	SOPHiA GENETICS Q4 Earnings Call Highlights (MarketBeat) -11.26%
06:45AM	SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results (PR Newswire)
Feb-25-26 08:00AM	SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference (PR Newswire)
Feb-18-26 09:41AM	Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy? (Zacks)
Feb-17-26 08:00AM	SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026 (PR Newswire)
Feb-10-26 09:22AM	SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems (PR Newswire)
Jan-12-26 07:00AM	SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan (PR Newswire)
Jan-07-26 08:00AM	SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology (PR Newswire)
Dec-12-25 10:15AM	AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave (PR Newswire)
Nov-25-25 07:46AM	Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How (Zacks)
09:00AM	Loading…
Nov-11-25 09:00AM	SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine (PR Newswire) +6.21%
08:01AM	SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine (PR Newswire)
Nov-08-25 08:00PM	Sophia Genetics SA (SOPH) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... (GuruFocus.com)
Nov-04-25 06:45AM	SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance (PR Newswire) -6.40%
Nov-03-25 08:04AM	Earnings To Watch: Sophia Genetics SA (SOPH) Reports Q3 2025 Result (GuruFocus.com)
Oct-21-25 08:00AM	SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025 (PR Newswire)
Oct-20-25 09:03AM	Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy? (Zacks)
Oct-16-25 11:00AM	A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan (PR Newswire)
04:01AM	SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology (PR Newswire)
Sep-23-25 08:01AM	Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy (PR Newswire)
Sep-22-25 08:00AM	SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer (PR Newswire) +18.37%
Sep-08-25 05:36AM	Jessa Ziekenhuis to adopt SOPHiA GENETICS platform for cancer care (Hospital Management)
Sep-05-25 04:00AM	SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of Pathology (PR Newswire)
Aug-19-25 09:33AM	Strategic Partnerships Power Tempus AI's Healthcare Expansion (Zacks)
Aug-13-25 03:00PM	Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold? (Zacks)
Aug-06-25 11:01AM	Sophia Genetics SA (SOPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -7.95%
Aug-05-25 06:45AM	SOPHiA GENETICS Reports Second Quarter 2025 Results (PR Newswire)
06:40AM	SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes (PR Newswire)
Aug-04-25 10:07AM	Sophia Genetics SA (SOPH) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-01-25 03:00PM	Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy? (Zacks)
Jul-22-25 08:00AM	SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025 (PR Newswire)
Jul-17-25 03:00PM	TEM Shares Surge on New AI Breakthrough: Should Investors Jump In? (Zacks)
Jun-09-25 03:00PM	Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today? (Zacks) -8.63%
May-15-25 03:00PM	After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order? (Zacks)
May-07-25 03:06AM	Sophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ... (GuruFocus.com)
May-06-25 07:55AM	SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:45AM	SOPHiA GENETICS Reports First Quarter 2025 Results (PR Newswire)
May-05-25 10:19AM	Earnings To Watch: Sophia Genetics SA (SOPH) Reports Q1 2025 Result (GuruFocus.com)
Apr-28-25 03:00PM	Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? (Zacks)
12:23PM	SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR (PR Newswire)
Apr-25-25 04:49AM	The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS (Zacks)
Apr-24-25 03:00PM	Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal? (Zacks)
Apr-22-25 08:00AM	SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025 (PR Newswire)
Apr-08-25 02:00AM	Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM Platform and its Liquid Biopsy Capabilities (PR Newswire)
Apr-01-25 03:00PM	Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? (Zacks)
Mar-21-25 12:00PM	SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-18-25 09:00AM	SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC (PR Newswire)
Mar-05-25 02:04AM	Sophia Genetics SA (SOPH) Q4 2024 Earnings Call Highlights: Record Customer Growth Amidst ... (GuruFocus.com)
Mar-04-25 07:55AM	SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -13.17%
06:45AM	SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results (PR Newswire)
Mar-03-25 07:21AM	What To Expect From Sophia Genetics SA (SOPH) Q4 2024 Earnings (GuruFocus.com)
Feb-24-25 04:03AM	Leading Healthcare Institutions Adopt MSK-ACCESS for Liquid Biopsy Testing (PR Newswire)
Feb-18-25 08:30AM	SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2024 on March 4, 2025 (PR Newswire) +11.22%
Jan-28-25 08:59AM	SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities (PR Newswire)
Nov-21-24 05:30AM	SOPHiA GENETICS Launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024 (PR Newswire)
Nov-06-24 06:59AM	SOPHiA GENETICS Faces Financial Challenges Amid Losses (TipRanks) -9.33%
02:08AM	Sophia Genetics SA (SOPH) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
12:10AM	Q3 2024 Sophia Genetics SA Earnings Call (Thomson Reuters StreetEvents)
Nov-05-24 06:32AM	SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer (PR Newswire)
06:30AM	SOPHiA GENETICS Reports Third Quarter 2024 Results (PR Newswire)
Nov-04-24 09:57AM	SOPHiA GENETICS SA (SOPH): A Bull Case Theory (Insider Monkey)
07:13AM	Sophia Genetics SA (SOPH) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-22-24 06:45AM	SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024 (PR Newswire)
Sep-14-24 09:00AM	SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024 (PR Newswire)
Sep-12-24 07:00AM	SOPHiA GENETICS Announces Poster Presentations at ESMO 2024 (PR Newswire)
04:00AM	SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024 (PR Newswire)
Sep-11-24 07:33AM	Sophia Genetics and AstraZeneca collaborate to expand liquid biopsy test rollout (Medical Device Network) +8.70%
Sep-10-24 10:28AM	SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing (PR Newswire)
Sep-05-24 08:30AM	SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024 (PR Newswire) +5.59%
Sep-04-24 06:00AM	SOPHiA GENETICS Unveils New Generation of the SOPHiA DDMTM Platform at Morgan Stanley Healthcare Conference 2024 (PR Newswire)
Aug-28-24 01:30PM	SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference (PR Newswire) +5.26%
Aug-14-24 09:13AM	Sophia Genetics secures CE mark for DDM analytics platform under EUs IVDR (Medical Device Network)
03:00AM	SOPHiA DDM Platform Certified Under IVDR (PR Newswire)
Aug-12-24 09:35AM	SOPHiA GENETICS (SOPH) Loses -30.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-09-24 12:00PM	What Makes SOPHiA GENETICS (SOPH) a New Buy Stock (Zacks)
Aug-06-24 07:55AM	SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:45AM	SOPHiA GENETICS Reports Second Quarter 2024 Results (PR Newswire)
Jul-29-24 10:30AM	SOPHiA GENETICS Announces L'hpital Universitaire Avicenne is Live on SOPHiA DDM (PR Newswire)
Jul-24-24 11:59AM	SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Menu Philippe	Chief Medical Officer	Oct 12 '26	Sale	7.26	5,000	36,303	195,993	Oct 14 04:04 PM
Xu Zhenyu	Chief Scientific Officer	Oct 13 '26	Sale	7.18	4,000	28,727	541,493	Oct 14 04:03 PM
Camblong Jurgi	Executive Chairman	Oct 12 '26	Sale	7.26	8,500	61,671	3,387,150	Oct 14 04:02 PM
Van Well Daan	Chief Legal Officer	Oct 05 '26	Sale	8.12	6,168	50,100	332,716	Oct 07 04:04 PM
Valente Manuela	Chief People Officer	Oct 05 '26	Sale	8.13	4,240	34,487	206,210	Oct 07 04:04 PM
Verma Abhimanyu	Chief Technology Officer	Oct 05 '26	Sale	8.12	5,284	42,929	166,887	Oct 07 04:04 PM
Puylaert Kevin	Chief Sales Officer	Oct 05 '26	Sale	8.04	216	1,737	147,732	Oct 07 04:04 PM
CARDOZA GEORGE	Chief Financial Officer	Oct 05 '26	Sale	8.10	1,592	12,897	306,726	Oct 07 04:04 PM
Menu Philippe	Chief Medical Officer	Oct 05 '26	Sale	8.13	7,394	60,100	200,993	Oct 07 04:04 PM
Camblong Jurgi	Executive Chairman	Oct 05 '26	Sale	8.13	40,172	326,526	3,395,650	Oct 07 04:04 PM
Xu Zhenyu	Chief Scientific Officer	Oct 05 '26	Sale	8.12	7,394	60,075	545,493	Oct 07 04:04 PM
Muken Ross	Chief Executive Officer	Oct 05 '26	Sale	8.13	9,838	79,971	660,391	Oct 07 04:03 PM
ZHENYU XU	Officer	Oct 05 '26	Proposed Sale	8.07	19,394	156,510		Oct 05 04:45 PM
DAAN GUIDO MARIA VAN WELL	Officer	Oct 05 '26	Proposed Sale	8.07	6,168	49,776		Oct 05 04:45 PM
ROSS J MUKEN	Director	Oct 05 '26	Proposed Sale	8.07	9,838	79,393		Oct 05 04:43 PM
PHILIPPE MENU	Officer	Oct 05 '26	Proposed Sale	8.07	22,394	180,720		Oct 05 04:43 PM
MANUELA VALENTE	Officer	Oct 05 '26	Proposed Sale	8.07	4,240	34,217		Oct 05 04:43 PM
GEORGE CARDOZA	Officer	Oct 05 '26	Proposed Sale	8.07	1,592	12,847		Oct 05 04:42 PM
JURGI CAMBLONG	Director	Oct 05 '26	Proposed Sale	8.07	65,672	529,973		Oct 05 04:41 PM
CARDOZA GEORGE	Chief Financial Officer	Sep 21 '26	Sale	8.33	774	6,447	308,318	Sep 22 04:02 PM
Muken Ross	Chief Executive Officer	Sep 21 '26	Sale	8.33	422	3,515	670,229	Sep 22 04:02 PM
GEORGE CARDOZA	Officer	Sep 21 '26	Proposed Sale	8.19	774	6,339		Sep 21 04:31 PM
ROSS J MUKEN	Director	Sep 21 '26	Proposed Sale	8.19	422	3,456		Sep 21 04:27 PM
Menu Philippe	Chief Medical Officer	Sep 14 '26	Sale	7.88	5,000	39,416	208,387	Sep 16 04:01 PM
Xu Zhenyu	Chief Scientific Officer	Sep 14 '26	Sale	7.88	4,000	31,538	552,887	Sep 16 04:01 PM
Van Well Daan	Chief Legal Officer	Sep 11 '26	Sale	7.63	6,168	47,089	338,884	Sep 14 04:01 PM
Camblong Jurgi	Executive Chairman	Sep 10 '26	Sale	7.66	8,500	65,120	3,435,822	Sep 14 04:01 PM
DAAN GUIDO MARIA VAN WELL	Officer	Sep 11 '26	Proposed Sale	7.61	6,168	46,938		Sep 11 04:30 PM
HIBBS KATHY L	Director	Sep 08 '26	Sale	8.13	6,250	50,818	96,992	Sep 10 04:02 PM
Xu Zhenyu	Chief Scientific Officer	Aug 27 '26	Sale	8.91	10,000	89,096	556,887	Aug 31 04:02 PM
ZHENYU XU	Officer	Aug 27 '26	Proposed Sale	8.53	14,000	119,420		Aug 27 04:24 PM
Menu Philippe	Chief Medical Officer	Aug 25 '26	Sale	8.68	5,000	43,396	213,387	Aug 26 04:04 PM
HIBBS KATHY L	Director	Aug 25 '26	Sale	8.68	6,250	54,233	103,242	Aug 26 04:04 PM
Verma Abhimanyu	Chief Technology Officer	Aug 24 '26	Sale	8.80	5,000	44,000	172,171	Aug 26 04:03 PM
Verma Abhimanyu	Chief Technology Officer	Aug 19 '26	Sale	8.20	5,000	41,000	177,171	Aug 26 04:03 PM
KATHY L HIBBS	Director	Aug 25 '26	Proposed Sale	8.45	18,750	158,438		Aug 25 04:44 PM
Valente Manuela	Chief People Officer	Aug 19 '26	Option Exercise	3.20	10,000	32,000	220,450	Aug 21 04:02 PM
Valente Manuela	Chief People Officer	Aug 19 '26	Sale	7.94	10,000	79,439	210,450	Aug 21 04:02 PM
Xu Zhenyu	Chief Scientific Officer	Aug 19 '26	Sale	7.94	10,000	79,427	576,887	Aug 21 04:01 PM
Xu Zhenyu	Chief Scientific Officer	Aug 21 '26	Sale	8.40	5,408	45,447	566,887	Aug 21 04:01 PM
Xu Zhenyu	Chief Scientific Officer	Aug 20 '26	Sale	8.41	4,592	38,609	572,295	Aug 21 04:01 PM
ZHENYU XU	Officer	Aug 20 '26	Proposed Sale	8.28	6,000	49,680		Aug 20 04:33 PM
MANUELA VALENTE	Officer	Aug 19 '26	Proposed Sale	7.62	10,000	76,200		Aug 19 04:30 PM
ZHENYU XU	Officer	Aug 19 '26	Proposed Sale	7.62	8,000	60,960		Aug 19 04:29 PM
Menu Philippe	Chief Medical Officer	Aug 12 '26	Sale	7.52	5,000	37,580	218,387	Aug 14 04:40 PM
Xu Zhenyu	Chief Scientific Officer	Aug 13 '26	Sale	7.52	4,000	30,076	586,887	Aug 14 04:40 PM
Verma Abhimanyu	Chief Technology Officer	Aug 07 '26	Sale	7.60	5,000	38,000	182,171	Aug 10 05:14 PM
Camblong Jurgi	Executive Chairman	Aug 07 '26	Sale	7.23	20,000	144,540	3,452,822	Aug 10 05:14 PM
Camblong Jurgi	Executive Chairman	Aug 10 '26	Sale	7.61	8,500	64,669	3,444,322	Aug 10 05:14 PM
Xu Zhenyu	Chief Scientific Officer	Aug 07 '26	Option Exercise	3.28	7,000	22,960	607,887	Aug 07 05:35 PM
Xu Zhenyu	Chief Scientific Officer	Aug 05 '26	Option Exercise	3.28	3,000	9,840	603,887	Aug 07 05:35 PM
Xu Zhenyu	Chief Scientific Officer	Aug 07 '26	Sale	7.29	17,000	123,911	590,887	Aug 07 05:35 PM
Xu Zhenyu	Chief Scientific Officer	Aug 05 '26	Sale	7.00	3,000	21,013	600,887	Aug 07 05:35 PM
ZHENYU XU	Officer	Aug 07 '26	Proposed Sale	6.69	22,000	147,180		Aug 07 04:35 PM
JURGI CAMBLONG	Director	Aug 07 '26	Proposed Sale	6.69	20,000	133,800		Aug 07 04:33 PM
Verma Abhimanyu	Chief Technology Officer	Aug 04 '26	Sale	6.95	5,000	34,772	187,171	Aug 05 04:14 PM
Camblong Jurgi	Executive Chairman	Aug 04 '26	Sale	6.92	20,000	138,412	3,472,822	Aug 05 04:14 PM
Xu Zhenyu	Chief Scientific Officer	Aug 04 '26	Sale	6.92	10,000	69,168	600,887	Aug 05 04:13 PM
JURGI CAMBLONG	Director	Aug 04 '26	Proposed Sale	5.69	20,000	113,800		Aug 04 04:37 PM
ZHENYU XU	Officer	Aug 04 '26	Proposed Sale	5.69	10,000	56,900		Aug 04 04:37 PM
Menu Philippe	Chief Medical Officer	Jul 27 '26	Sale	5.66	5,000	28,306	223,387	Jul 28 04:03 PM
Camblong Jurgi	Executive Chairman	Jul 20 '26	Option Exercise	3.16	4,581	14,476	3,517,403	Jul 22 04:01 PM
Camblong Jurgi	Executive Chairman	Jul 20 '26	Sale	6.29	24,381	153,445	3,512,822	Jul 22 04:01 PM
Camblong Jurgi	Executive Chairman	Jul 21 '26	Sale	6.63	20,000	132,654	3,492,822	Jul 22 04:01 PM
JURGI CAMBLONG	Director	Jul 21 '26	Proposed Sale	6.33	37,000	234,210		Jul 21 04:24 PM
JURGI CAMBLONG	Director	Jul 20 '26	Proposed Sale	5.87	24,381	143,116		Jul 20 04:15 PM
Menu Philippe	Chief Medical Officer	Jul 13 '26	Sale	5.70	5,000	28,505	228,387	Jul 14 04:02 PM
Xu Zhenyu	Chief Scientific Officer	Jul 13 '26	Sale	5.70	4,000	22,819	610,887	Jul 14 04:02 PM
Camblong Jurgi	Executive Chairman	Jul 10 '26	Sale	5.62	8,500	47,791	3,532,622	Jul 14 04:02 PM
Camblong Jurgi	Executive Chairman	Jul 07 '26	Sale	5.28	17,685	93,327	3,541,122	Jul 08 04:01 PM
JURGI CAMBLONG	Director	Jul 07 '26	Proposed Sale	5.34	24,290	129,709		Jul 07 04:40 PM
CARDOZA GEORGE	Chief Financial Officer	Jul 06 '26	Sale	5.29	1,592	8,419	309,092	Jul 07 04:04 PM
Valente Manuela	Chief People Officer	Jul 06 '26	Sale	5.05	4,241	21,430	210,450	Jul 07 04:03 PM
Verma Abhimanyu	Chief Technology Officer	Jul 06 '26	Sale	5.10	5,285	26,957	192,171	Jul 07 04:03 PM
Xu Zhenyu	Chief Scientific Officer	Jul 06 '26	Sale	5.17	7,393	38,242	614,887	Jul 07 04:03 PM
Muken Ross	Chief Executive Officer	Jul 06 '26	Sale	5.22	9,838	51,354	670,651	Jul 07 04:03 PM
Puylaert Kevin	Chief Sales Officer	Jul 06 '26	Sale	5.03	216	1,087	147,948	Jul 07 04:03 PM
Menu Philippe	Chief Medical Officer	Jul 06 '26	Sale	5.16	7,393	38,156	233,387	Jul 07 04:03 PM
Camblong Jurgi	Executive Chairman	Jul 06 '26	Sale	5.25	22,486	118,164	3,558,807	Jul 07 04:03 PM
PHILIPPE MENU	Officer	Jul 06 '26	Proposed Sale	5.35	32,393	173,303		Jul 06 04:42 PM
ZHENYU XU	Officer	Jul 06 '26	Proposed Sale	5.35	19,393	103,753		Jul 06 04:42 PM
GEORGE CARDOZA	Officer	Jul 06 '26	Proposed Sale	5.35	1,592	8,517		Jul 06 04:39 PM
ROSS J MUKEN	Officer	Jul 06 '26	Proposed Sale	5.35	9,838	52,633		Jul 06 04:31 PM
MANUELA VALENTE	Officer	Jul 06 '26	Proposed Sale	5.35	4,241	22,689		Jul 06 04:27 PM
Camblong Jurgi	Executive Chairman	Jun 30 '26	Option Exercise	3.16	45,419	143,524	3,646,562	Jul 01 04:03 PM
Camblong Jurgi	Executive Chairman	Jun 29 '26	Option Exercise	3.16	18,060	57,070	3,619,553	Jul 01 04:03 PM
Camblong Jurgi	Executive Chairman	Jun 30 '26	Sale	6.11	65,269	398,632	3,581,293	Jul 01 04:03 PM
Camblong Jurgi	Executive Chairman	Jun 29 '26	Sale	5.87	18,410	108,058	3,601,143	Jul 01 04:03 PM
JURGI CAMBLONG	Director	Jun 30 '26	Proposed Sale	5.98	70,000	418,600		Jun 30 04:32 PM
JURGI CAMBLONG	Director	Jun 29 '26	Proposed Sale	5.75	20,000	115,000		Jun 29 04:45 PM
Camblong Jurgi	Chief Executive Officer	Jun 26 '26	Option Exercise	3.16	31,940	100,930	3,633,433	Jun 29 04:07 PM
Camblong Jurgi	Chief Executive Officer	Jun 26 '26	Sale	5.80	50,069	290,329	3,601,493	Jun 29 04:07 PM
Camblong Jurgi	Chief Executive Officer	Jun 25 '26	Sale	5.70	1,373	7,826	3,619,622	Jun 29 04:07 PM
JURGI CAMBLONG	Director	Jun 26 '26	Proposed Sale	5.69	68,129	387,654		Jun 26 04:31 PM
Verma Abhimanyu	Chief Technology Officer	Jun 25 '26	Sale	5.51	6,944	38,229	197,456	Jun 26 04:03 PM
Menu Philippe	Chief Medical Officer	Jun 25 '26	Sale	5.50	5,000	27,524	240,780	Jun 26 04:03 PM
JURGI CAMBLONG	Director	Jun 25 '26	Proposed Sale	5.52	1,373	7,579		Jun 25 04:31 PM
CARDOZA GEORGE	Chief Financial Officer	Jun 22 '26	Sale	5.38	774	4,164	310,684	Jun 23 04:01 PM
Muken Ross	President	Jun 22 '26	Sale	5.38	422	2,270	680,489	Jun 23 04:01 PM
GEORGE CARDOZA	Officer	Jun 22 '26	Proposed Sale	5.46	774	4,226		Jun 22 04:49 PM

SOPHiA GENETICS SA is a healthcare technology company, which engages in the practice of data driven medicine as the standard of care and for life sciences research. It operates through the following geographical segments: France, Italy, United States, Spain, Turkey, Austria, Brazil, United Kingdom, Switzerland, Germany, and Other. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Ph.D.Dr. Jurgi Camblong M.B.A.

CEO & DirectorMr. Ross Jordan Muken B.Sc.

Executive VP & CFOMr. George A. Cardoza M.B.A.

EVP & Chief Technology OfficerMr. Abhimanyu Verma

Executive VP & Chief Scientific OfficerDr. Zhenyu Xu Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SOPH

SOPHiA Genetics SA

Upgrade your Finviz experience